Gene therapy by cell specific targeting

Details Gene therapy by cell specific targeting Gene therapy by cell specific targeting

2006-01-03

2006-01-03

Wehbé, Anne M. (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093200, C424S093100, C514S04400A, C435S069100, C435S320100, C435S325000, C435S335000, C435S355000, C435S372000

Reexamination Certificate

active

06982082

ABSTRACT:
This invention is directed to a modified cyclosporin A and to a modified, genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by transfecting stem cells so that after introduction into a patient the stem cells will express the modified cyclophilin, and, as necessary, administer the modified cyclosporin A to the patient.

REFERENCES:
patent: WO 94/18317 (1994-08-01), None
patent: WO 95/02684 (1995-01-01), None
patent: WO 96 06097 (1996-02-01), None
patent: WO 96 12806 (1996-05-01), None
Bron, D. (1994) Curr. Opin. Oncol., vol. 6, 358-364.
Hertenstein et al. (Feb. 1998) BioDrugs, vol. 9 (2), 105-123.
Blazer et al. (1997) Immunological Reviews, vol. 157, 79-109.
Deonarin et al. (Jan. 1998) Exp. Opin. Ther. Patents, vol. 8 (1), 53-69.
Miller et al. (1995) FASEB, vol. 9, 190-199.
Mori et al. (1997) J. Immunol., vol. 158, 3659-3665.
Fruman et al. Molecular and Cellular Biology 15:3857-3863, 1995.
Kawamura et al. The Journal of Biological Chemistry 270:15463-15466, 1995.
Futer O., “FK506 Binding Protein Mutational Analysis”, 270/32 J. Biol. Chem., 18935-18940 (1995).
DeCenzo, M.T., “FK506-binding Protein Mutational Analysis: Defining the Active Site Residue Contributions to Catalysis and the Stability of Ligand Complexes”, 9/2 Protein Engineering, 173-180, (1996).
Luengo J.I., “Structure-Activity Studies of Rapamycin Analogs: Evidence that the C-7 Methoxy Group is Part of the Effector Domain and Positioned at the FKBP 12-FRAP Interface”, 2/7 Chemistry and Biology 471-481 (1995).
Brown et al. “A signalling pathway to translational control” Cell, 86:517 (1996).
Hung et al. “Understanding and controlling the cell cycle with natural products” Chemistry & Biology 3: 623 (1996).
Belshaw et al. “Rational design of orthogonal receptor-ligand combinations” Angew. Chem. Int. Ed. Engl. 34:2129 (1995).
Rosen et al. “Natural products as probes of cellular function: studies of immunophilins” Angew. Chem. Int. Ed. Engl. 31: 384 (1992).
International Search Report mailed Apr. 29, 1998.

Affiliated with

Also associated with

Rating

Gene therapy by cell specific targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene therapy by cell specific targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy by cell specific targeting will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3536492